2026.5.19
TCROSS Co., Ltd. announced that, on May 18, 2026, the Japan Patent Office issued a patent approval for inventions related to the core functions of its pharmaceutical and medical device sales and marketing platform, “InsighTCROSS,” namely “ActionOptimizer” and “ValueTracer.”
The title of the invention is “Medical Sales Support Information Processing Device and Method.” ActionOptimizer, one of the technologies covered by the patent approval, is a function that calculates the probability of product usage or prescription for individual physicians by analysing physician attributes and sales and marketing activity histories using logistic regression analysis. Based on these calculations, the system identifies and recommends the optimal sales and marketing actions required to increase prescription probability.
Traditionally, pharmaceutical sales and marketing activities have relied heavily on experience and intuition, making it difficult to quantitatively determine which activities truly influenced prescribing behavior.
This technology enables pharmaceutical and medical device companies to reduce ineffective activities while concentrating resources on activities with measurable impact on prescriptions and sales. By integrating scientific analysis into commercial decision-making, InsighTCROSS supports a more data-driven and efficient approach to sales and marketing strategy.
ValueTracer, which was also included in the patent approval, is a function designed to quantitatively evaluate the return on investment (ROI) of individual sales and marketing activities. The patent claims include a mechanism for calculating the relative impact of each promotional activity on sales and deriving ROI based on those relative impact scores.
ValueTracer allows companies to visualise annual ROI by activity type, thereby supporting strategic decisions regarding “what should be reduced” and “what should be reinforced.” By adding quantitative evaluation to traditionally qualitative decision-making processes, the system enables more rational allocation of limited commercial resources.
In addition, the approved patent also includes technology related to physician similarity analysis using cosine similarity calculations, which partially covers technologies associated with “MedLinker,” another function within InsighTCROSS.
TCROSS will present these patented technologies, including ActionOptimizer and ValueTracer, at Pharma Digital Transformation Expo Tokyo 2026, which will be held at Makuhari Messe from May 20 to May 22, 2026.
Comment from Satoru Hashimoto, CEO of TCROSS
“For many years, the pharmaceutical industry has faced challenges in quantitatively explaining which activities truly contributed to commercial outcomes. We believe this patent approval recognizes the core technology behind InsighTCROSS, which scientifically analyses and optimizes sales and marketing activities. We will continue contributing to digital transformation in healthcare and to the creation of more rational and sustainable commercial strategies.”